Associated tags: Ulcerative colitis, Cystic fibrosis, FW, First wave, Niclosamide, Nutrient, Digestion, CP, Exocrine pancreatic insufficiency, Patient, Fats, BOCA, Pharmaceutical industry, EPI, Clinical trial
Locations: NEW YORK CITY, CALIFORNIA, NY, WASHINGTON, RALEIGH, BRAZIL, MASSACHUSETTS, BOSTON, NEWPORT BEACH, BOCA RATON, FL, US, PUERTO RICO, NEW JERSEY, EPI, CF, FLORIDA
Biotechnology,
U.S. Securities and Exchange Commission,
Marketing,
Cystic fibrosis,
CP,
FW,
Yarrowia,
Acquisition,
Compliance,
AAPS,
Research,
CRO,
CEO,
Patient,
Program,
CF,
ROI,
EPI,
Capsule,
Diarrhea,
Niclosamide,
Company,
Clinical trial,
Research Triangle Park,
Security (finance),
Nutrient,
GLOBE,
Cystic Fibrosis Foundation,
Exocrine pancreatic insufficiency,
Food,
Fats,
NASDAQ,
Weight loss,
Drug development,
BOCA,
PERT,
Gastrointestinal tract,
First wave,
Ulcerative colitis,
Digestion,
Stomach,
Pharmaceutical industry,
Rho,
Facebook First Wave BioPharma is developing adrulipase as a treatment for exocrine pancreatic insufficiency (EPI) associated with cystic fibrosis (CF) and chronic pancreatitis (CP).
Key Points:
- First Wave BioPharma is developing adrulipase as a treatment for exocrine pancreatic insufficiency (EPI) associated with cystic fibrosis (CF) and chronic pancreatitis (CP).
- Under the agreement, Rho will manage the Phase 2 clinical trial of the microgranule drug delivery formulation of adrulipase.
- We are eager to evaluate the potential of our new formulation in the proof-of-concept Phase 2 clinical trial, which we expect to initiate before year-end.
- We look forward to being a valued partner to First Wave BioPharma in the management of the soon-to-be-initiated Phase 2 trial.
Retrieved on:
Friday, September 30, 2022
Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
Key Points:
- Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
- Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.
- InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street.
- We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.
Retrieved on:
Tuesday, November 30, 2021
Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
Key Points:
- Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
- Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.
- InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street.
- We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.
